Description du projet
De jeunes chercheurs font de la fibrillation auriculaire une affaire personnelle
Le cœur se compose de quatre cavités qui se contractent et se détendent de manière coordonnée pour pomper le sang. Un dysfonctionnement dans ce processus peut entraîner un essoufflement, des étourdissements et de la fatigue dans les cas bénins et une insuffisance cardiaque dans les cas plus graves. Dans la fibrillation auriculaire, les deux cavités supérieures du cœur (les oreillettes) battent rapidement et irrégulièrement, augmentant ainsi le risque d’accident vasculaire cérébral et de maladies connexes. Il existe de nombreuses causes possibles et identifier la cause exacte pour chaque patient est essentiel pour mettre en œuvre un traitement efficace. PersonalizeAF développe de nouvelles technologies pour caractériser la fibrillation auriculaire, complétées par de nouvelles stratégies de traitement. Le réseau conjoint de formation universitaire et clinique prévoit de fournir des thérapies personnalisées et de meilleurs résultats.
Objectif
Atrial Fibrillation (AF) is the most common cardiac arrhythmia affecting more than 6 million Europeans with a cost exceeding 1% of the EU health care system budget (13.5 billion annually). New treatment strategies and the progress achieved in research on AF mechanisms and substrate evaluation methods to date have not been commensurate with an equivalent development of the knowledge and technologies required to individually characterize each patient in search of the most efficient therapy.
PersonalizeAF addresses this challenge by delivering an innovative multinational, multi-sectorial, and multidisciplinary research and training programme in new technologies and novel strategies for individualized characterization of AF substrate to and increase treatments’ efficiency.
From the research point of view, PersonalizeAF will integrate data and knowledge from in-vitro, in silico, ex vivo and in vivo animal and human models to: 1) generate an individual description of the state of the atrial muscle identifying the disease mechanisms and characteristics; 2) understanding the potential effect that different therapies have on different atrial substrates; and 3) combining this information to generate a specific profile of the patient and the best therapy for each patient.
With this purpose, PersonalizeAF partnership aggregates relevant scientific staff from the academic and clinical world with highly specialised biomedical companies which will be involved in a high-level personalised training programme that will train a new generation of highly skilled professionals and guarantee ESRs and future PhD students outstanding Career Opportunities in the biomedical engineering, cardiology services and medical devices sectors. PersonalizeAF will disseminate results to a wide spectrum of stakeholders, create awareness in the general public about atrial fibrillation and encourage vocational careers among young students.
Champ scientifique
Mots‑clés
Programme(s)
Régime de financement
MSCA-ITN - Marie Skłodowska-Curie Innovative Training Networks (ITN)Coordinateur
46022 Valencia
Espagne